Fund moves
24 tracked managers disclosed the same change for Q1 2025. From a 13F filed May 15, 2025 covering holdings at Mar 31, 2025 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded May 12, 2025 · Filed May 14, 2025
The CEO of Viatris paid $536K out of pocket for Viatris shares. It was the first purchase in over a year. Shares held went up 26% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$536,262
Shares × reported transaction price
$500K–$1M
+25.8%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
None in 53 months of history
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 3.6% of the CEO's reported total pay for fiscal 2024 ($14.8M)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-02. The proxy names Scott A. Smith as CEO for that year. A size comparison, not a judgement
4 days after results of May 8, 2025, 87 days before results of Aug 7, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Emtricitabine, Rilpivirine and Tenofovir Disoproxil Fumarate on May 20, 2025, 8 days after this trade.
Generic drug approved. Active ingredient: Emtricitabine, Rilpivirine Hydrochloride, Tenofovir Disoproxil Fumarate. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −3.3% | −1.3% | −2.0% |
| 30 days | +2.3% | +2.1% | +0.2% |
| 90 days | +18.4% | +9.2% | +9.2% |
| 180 days | +27.4% | +15.7% | +11.8% |
| 365 days | +87.5% | +25.2% | +62.3% |
Past results only. Not a forecast.
Fund moves
24 tracked managers disclosed the same change for Q1 2025. From a 13F filed May 15, 2025 covering holdings at Mar 31, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
8 tracked managers disclosed the same change for Q4 2024. From a 13F filed May 15, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
Fund moves
24 tracked managers disclosed the same change for Q1 2025. From a 13F filed May 14, 2025 covering holdings at Mar 31, 2025 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.